|17th December 2020||Edward Wholihan||68,550||Open or private sale||$1.36||$93,228.00|
|17th December 2020||Edward Wholihan||164,822||Exercise of derivative||$0.00|
|17th December 2020||Louis Md Brenner||103,116||Open or private sale||$1.36||$140,237.76|
|17th December 2020||Louis Md Brenner||247,932||Exercise of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Allena Pharmaceuticals, Inc. engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes Reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011.